 CAMBRIDGE, Mass., Oct. 13, 2021 GLOBE NEWSWIRE -- Sarepta Therapeutics, Inc. NASDAQ:SRPT, the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of 6,172,840 shares of its common stock at a price to the public of 81.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 925,926 shares of its common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately 500.0 million, excluding any exercise of the underwriters option to purchase additional shares. The offering is expected to close on or about October 18, 2021, subject to customary closing conditions. 